Subsequent anti-VEGF therapies, such as ranibizumab (Lucentis) and bevacizumab (Avastin), proved to be more effective in treating various retinal conditions, including AMD and DME [27]. This evidence concerns the gene VEGFA and age-related macular degeneration.